List of Radiopharmaceuticals/Radiotherapies Companies in United States - 74

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies.

Nasal breathing is a very important function of human life and any obstruction in the nasal airway also known as a congested or blocked nose, can dramatically impact the quality of life.The VIVAER treatment, performed in a doctor’s office, is a non-invasive procedure without any incisions. The patient'snasal valve area is gently reshaped using low-temperature radiofrequency energy with lasting results.

Affera is a venture-backed medical device company founded by a seasoned team of leaders in the industry. We are developing an innovative system to treat heart rhythm disorders, a prevalent condition affecting millions of patients worldwide. Follow us as we share updates about our progress.

Aktis Oncology is a biotechnology company dedicated to realizing the curative power of alpha radiopharmaceuticals for the mainstream of cancer care.

Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.

Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope.  Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer.  The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products.  For more information please visit www.macrocyclics.com.

Arizona Isotope Science Research Corporation (AZI), was formed in 2017 and specializes in nuclear medicine and the production of isotopes that are beneficial to medical research and treatment.

ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.

BAMF Health is the world's first vertically integrated platform for molecular imaging and radiopharmaceutical therapy. Using the most advanced imaging and therapy technologies, BAMF Health is dedicated to providing comprehensive and intelligent treatment options for patients with serious health issues such as cancer, heart disease, and stroke.

CancerTargetedTechnology develops innovative agents for cancer that accurately detect early and advanced disease, monitor treatment efficacy

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, Instagram, YouTube, and Facebook.

At Chimerix, we are on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. With a focus in oncology, we are devoted to filling gaps in the treatment paradigm.

CivaTech Oncology® designs innovative products that bring meaningful improvements to low dose rate brachytherapy. The CivaString® and CivaSheet™ can substantially reduce procedure time, provide homogeneous dose distribution and minimize trauma. Customizable CivaTech products ensure that radiation oncologists can deliver individualized, targeted therapy to treat cancer. http://www.civatechoncology.com/

Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.

Coquí RadioPharmaceuticals is a radiopharmaceuticals company focused on creating a scalable and reliable domestic supply of Mo-99 to provide low-cost diagnostics and treatments to patients.

Curadh is pioneering the eradication of solid tumors through the new science of molecularly targeted radiation. With expertise in transitioning from Pre-Clinical to the Clinic, Curadh incorporates scientific excellence and product development strategy.

Cynosure is a leader in the medical devices industry specializing in aesthetic medicine and cosmetic procedures.

D&D is a clinical-stage global biotech company that focuses on development and commercialization of revolutionary medicines with the potential to change the lives of patients with unmet medical needs. Our success is built on a product pipeline originating from top research centers.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Evergreen Theragnostics was established in 2019 to be a leading US-based radiopharmaceutical Contract Development and Manufacturing Organization (CDMO). Our team’s expertise and track record in theragnostic radiopharmaceutical commercialization, manufacturing process development, and regulatory affairs management, make us your ideal partner for all of your radiopharmaceutical development, manufacturing, and commercialization needs.

Fuzionaire Theranostics is a radiopharmaceutical company on a mission to make theranostic treatments more accessible to people with cancer. With origins in Nobel laureate Robert Grubbs' lab at Caltech, the company's patented HetSiFA® platform offers manufacturing advantages in a clinical setting and enables a personalized therapeutic dose for each cancer patient. Current development plans address pressing clinical needs in prostate and lung cancer. For more, visit us at: www.fuzionairetx.com

Galera Therapeutics is focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.

GT Medical Technologies, Inc. (GT), an Arizona-based medical device company, is focused on improving the lives of patients with brain tumors. GT has developed an innovative approach to treatment by combining a conformable collagen matrix with brachytherapy (radiation) seeds. The product has the promise to revolutionize treatment for 176,000 patients/year in the US alone. To date, we have treated 1000+ patients with brain tumors.

Gynesonics is a medical technology company that specializes in providing minimally invasive solutions for women's health, particularly in the treatment of uterine fibroids.

ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.

IntraOp Medical is a medical devices company that specializes in electron therapy devices for treating cancer, providing compact and mobile linear accelerators for effective and precise radiation therapy at the point of care.

Invicro is a company in the medical imaging and biotechnology industry that specializes in imaging services for pharmaceutical and life sciences companies.

Ionetix is a Michigan-based medical device firm that designs and develops cyclotron technology-based radioisotope equipment for cancer diagnosis and therapeutic applications.

We develop novel therapeutic and diagnostic agents directed at severe diseases. Our specialty is therapeutic radiopharmaceuticals. IsoTherapeutics has been acquired by Telix Pharmaceuticals.

Jubilant Pharma Limited is a global integrated pharmaceutical company offering a wide range of products and services to our customers across geographies. We organize our business into two segments, namely, Specialty Pharmaceuticals, comprising Radiopharmaceuticals (including Radiopharmacies), Contract Manufacturing of Sterile Injectables and Non-sterile Products and Allergy Therapy Products, and Generics & APIs, comprising Solid Dosage Formulations and Active Pharmaceutical Ingredients.

KeraNetics is the global leader in keratin science, purified, human-derived keratin manufacture, research and development for healthier wound healing KeraNetics provides physicians with new options to help patients by exploiting the properties of purified, human-derived keratin. KeraStat® Cream: Better management of radiation dermatitis (RD). KeraStat® Cream harnesses the power of keratin proteins to support the management of dry, light, and moderately exuding partial thickness skin wounds such as radiation dermatitis resulting from a fractionated radiotherapy regimen. FDA cleared and available in 1 oz. and 5 mL tubes. Rx only.

Know Labs is transforming non-invasive medical diagnostics. The proprietary technology platform uses radiofrequency (RF) dielectric spectroscopy and can be integrated into a variety of wearable, mobile, or bench-top form factors. The first application is a non-invasive continuous blood glucose monitoring device that will provide the user with real-time information on their blood glucose levels, assisting billions of people with diabetes and prediabetes to manage this medical condition. Know Labs is a public company whose shares trade under the stock symbol KNW (NYSE American).

Lantheus Holdings, Inc. (NASDAQ: LNTH) is the parent company of Lantheus Medical Imaging, Inc. (LMI), which is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. LMI’s key products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs.

Life-saving therapies. Critical diagnostics. Breakthrough clinical trials. Life Couriers places hope in the hands of patients everywhere by being the world's most trusted logistics partner for crucial pharmaceutical and medical products. We are the worldwide market leader for radiopharmaceutical and stem cell logistics. We have taken this experience with the most time-critical shipments in the world to expand our services to biopharmaceuticals, cell and gene therapies, lab specimens, clinical trials, organ transplant, medical devices, and more. We understand a fundamental reality - that missing a delivery can mean losing a life. That is why we have intentionally curated our culture to be solely focused on patient outcomes. Our people care more and they are deeply committed to enhancing, enriching, and saving lives through the power of logistics. We are Life Couriers. Logistics for Life.

Litron has spent the last 40 years providing critical data to pharmaceutical, medical device, government and contract research organizations around the world. With a laser focus on DNA damage and other toxic effects, we develop state-of-the-art flow cytometric methods to solve challenging problems for the toxicology industry.

Mariana Oncology is a fully integrated next generation radiopharmaceutical company that brings together experts in ligand discovery, radiochemistry, radiobiology and oncology translational and clinical research in order to build a pipeline across a range of solid tumor types. Our mission at Mariana is to discover and develop safe, effective, and highly targeted radiopharmaceuticals.

Matrix Biomed, Inc. is a biopharmaceutical company focused on delivering gene-based therapeutics. Gene-based therapeutics are directed to address both the dysregulation of multiple genes as well as their interactions in gene regulatory networks. Only by addressing the dysregulation of multiple genes and their interactions in gene regulatory networks, Matrix Biomed, Inc. is able to deliver a therapy designed to truly revert a disease state to healthy state. Currently, Matrix Biomed, Inc. gene-based therapeutics are directed to therapies and drug products to make cancer treatment more manageable and successful through the elimination of the dose-limiting, life-threatening, and treatment-inhibiting toxicities associated with chemotherapy and radiotherapy while targeting the master genes responsible for cancer growth and development, hypoxia inducible factor -1 (HIF-1) and hypoxia inducible factor-2 (HIF2).

Restech offers minimally invasive tools to multiple specialties in order to accurately diagnose and manage reflux, and will continue to create solutions related to the complexity gastric related diseases. Restech’s tools are helping evolve the standard of care for patients with reflux, and fecal incontinence, providing physicians with the necessary data to transform the algorithm of care for tens of millions of patients.

Meditope Biosciences, Inc. is in possession of a revolutionary antibody platform technology called “SnAP” (Site-specific, novel, Antibody Platform), which can turn antibodies into a LEGO-like system. The power, elegance, and simplicity of SnAP allows for a broad range of molecules – toxins, proteins, radiolabels, other antibodies – to be ‘snapped’ on or off an antibody with predictability, precision and control. Meditope is using this technology to develop a preclinical pipeline of compelling cancer drugs including two new immuno-oncology product for prostate and bladder cancers.

Mirae Asset Global Investments operates across 15 markets, where we take a collaborative approach in managing a fully diversified investment platform that spans all major asset classes. Powered by a unique perspective and the expertise of our global investment professionals, we adapt to our clients’ evolving needs, providing them with innovative investment solutions and intelligent ways to achieve their investment objectives. We currently invest over $256bn on behalf of clients, giving us the scale and experience to identify opportunities in a changing world. (Data as of June 2024) Important information: http://www.miraeasset.com/other/social-media-policy

Monopar Therapeutics is a clinical­-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR­101, a late-­stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR­202, an early-stage camsirubicin analog for various cancers.

Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is a leader in precision medicine with immuno-targeted products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Applying our Manocept™ technology, Navidea seeks to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases, with an initial focus on personalized Rheumatoid Arthritis diagnostics. The company, founded in 1983, maintains headquarters in Dublin, Ohio.

NeuroOne Medical Technologies is a medical device company that specializes in developing high-definition, minimally invasive thin film electrodes for the diagnosis and treatment of various neurological conditions.

At NorthStar Medical Radioisotopes, our mission is to provide patients global access to game-changing radiopharmaceuticals. We are a growing, commercial-stage company focused on advancing patient care by providing therapeutic radioisotopes and novel radiopharmaceuticals to detect and treat cancer, and customized radiopharmaceutical development services. Radiopharmaceutical therapy is increasingly important for cancer treatment, and NorthStar is expanding our industry-leading position in developing commercial-scale production technologies to meet this important healthcare need. We routinely produce the therapeutic radioisotope copper-67 (Cu-67) and are poised to be one of the first commercial-scale producers of non-carrier-added (n.c.a.) actinium-225 (Ac-225), using first-in-kind and environmentally preferable electron accelerator technology. NorthStar’s Radiopharmaceutical Contract Development and Manufacturing Organization (CMDO/CMO) unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercial programs. At NorthStar, we prioritize professional growth of our employees. Working with our cutting-edge technology offers a stimulating and rewarding environment for talented individuals who want to be part of our exciting and growing business. We are committed to providing our employees with fulfilling work experiences and valuable career development opportunities.

Nucleus RadioPharma is a full-service Contract Development and Manufacturing Organization (CDMO) dedicated to building robust and reliable clinical and commercial supply chains for targeted radiotherapies.

No patient should be denied the cancer care they need simply because some options are in short supply or unavailable. Yet, all too often, this is what happens. Nusano is a physics company that creates radioisotopes—tiny tracers used by doctors to diagnose and treat cancer and other diseases. Doctors use these tiny tracers like flashlights to light up areas inside the body. They can see how blood is flowing, how organs are functioning, even how cells are growing. Advanced medicines and treatment methods also use radioisotopes to target and eliminate cancer cells with precision. Health care has used radioisotopes for decades. But, if supply does not keep up with demand, patients will lose out on the benefits of these lifesaving, proven tools. Nusano's patented technologies and methods are poised to transform radioisotope production and usher in an exciting new era in cancer care. Our state-of-the-art facility in West Valley City, Utah will produce radioisotopes quickly, efficiently, and affordably. This will make desperately needed resources available to hospitals and cancer clinics around the world and offer those with life-threatening diseases hope for a healthier tomorrow.

NuView Life Sciences is a clinical stage precision oncology company. The Vasoactive Intestinal Peptide/Pituitary Adenylate Cyclase-activating Peptide Receptor is over-expressed on the surface of a wide range of cancer types at the onset of oncogenesis. NuView's NV-VPAC1 small molecule binding agent designed to identify and bind to the VPAC receptors has been utilized in clinical trials for binary in vitro and in vivo of confirmation of cancer. The NV-VPAC1 agent can be utilized to deliver existing therapeutics and new alpha and beta emitters. NuView will pair existing imaging and therapeutic radionuclides with NuViews proprietary agent and provide a Theranostics solution for patients and clinicians.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial. The company is also developing DocePLUS, a patented chemotherapy for patients with solid tumors that is in Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy for patients with ovarian cancer. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx’s glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Precision Molecular (PMI) is a clinical-stage company developing imaging biomarkers and theranostics for patients with cancer. They specialize in molecular imaging.

Q BioMed Inc. is a biotech acceleration and commercial stage company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

RadioMedix, Inc. is a biotechnology company, based in Houston, Texas, focused on innovative targeted radio-pharmaceuticals for diagnosis, monitoring and therapy of cancer. The company is commercializing generator-produced radio-pharmaceuticals based on Gallium-68 chemistry. RadioMedix is in late-stage development of a new radio-labeled analog targeting metabolic pathway, GlucoMedix, which is based on its patented DO2A-chelation technology. RadioMedix is introducing the SmartMedix™ automated laboratory system for synthesis of PET tracers for the research and clinical markets. RadioMedix has also established two service facilities for academic and industrial partners: cGMP Manufacturing Suite for clinical probe development and Molecular Imaging Facility for evaluation of agents in animal models.

Building out a pipeline of small molecule radiopharmaceuticals targeting novel G-protein coupled receptors (GPCRs) to treat a range of cancers.

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.

Leader in targeted radiopharmaceuticals to improving cancer patient survival. Broad pipeline of innovative drugs against solid tumor targets

The company uses biology-guided radiotherapy to detect and respond to signals emitted from cancer cells, and use them to guide treatment.

Regen BioPharma Inc. is a publicly traded biotechnology company focused on developing innovative treatments using autologous cell therapies, RNA and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmune disease space.

S4 Medical is committed to developing solutions for safer and more effective catheter ablation treatment for atrial fibrillation.

SalutarisMD is a medical device company that specializes in engineering a novel ophthalmic treatment for Wet age-related Macular Degeneration with a minimally invasive procedure.

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive, and cost-effective treatments for both oncological and non-oncological conditions. Offering proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world. TransDermal Infusion delivers HA, Botox, Fillers, Hair Restoration, PRP & more without needles, downtime.

Shasqi is a privately held, clinical stage biopharmaceutical company who is focused on bringing the advances of click chemistry to help people fight their cancer. The Click Activated Protodrugs Against Cancer (CAPAC™) Platform is a therapeutic modality based on click chemistry, which utilizes the biocompatible chemical reaction between an attenuated trans-cyclooctene-modified protodrug and a tetrazine-modified biopolymer. The biopolymer is injected in the desired tumor, which then captures and activates an infused protodrug precisely at the tumor site.

SHINE Technologies accelerates a practical, incremental four-phase pathway to clean, abundant fusion energy, starting with using fusion technology to solve today's problems in medicine, manufacturing, energy, and beyond. #SHINETogether #FusionTechnology

SkinCure Oncology is the only company offering GentleCure™—the most comprehensive approach to delivering advanced, nonsurgical treatment for basal cell carcinoma, squamous cell carcinoma, and other skin cancers using Image-Guided SRT. The company partners with quality-focused dermatologists and Mohs surgeons to bring cancer center-level radiation therapy to physician offices. From clinical, administrative, and operational backing to robust patient support, SkinCure Oncology ensures that practices are fully equipped to offer treatment with Image-Guided SRT. This advanced technology delivers calibrated doses of X-ray energy via the Sensus SRT-100 Vision™, the first and only skin cancer treatment platform with high-frequency ultrasound imaging. Adaptive radiotherapy protocols destroy malignant cancer cells while preserving healthy tissue surrounding the treated areas for optimal clinical and cosmetic outcomes and the ideal patient experience.

Our vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (theranostics). With our robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value radiopharmaceutical intellectual property, we are poised to deliver on the promise of radiopharmaceuticals. www.sofie.com www.twitter.com/sofiebio www.instagram.com/sofiebio

Solta Medical, a division of Bausch Health Companies Inc., is a global leader in the medical aesthetics industry. Established in 1995, we are headquartered in Bothell, WA with field teams and regional offices worldwide. For over a decade, we have continued to deliver sophisticated technology that provides therapeutic benefits. With over 5 million procedures performed worldwide, our technologies are proven and effective options for consumers and physicians alike. Our portfolio includes the Thermage®, Fraxel®, Clear + Brilliant®, and VASERlipo® systems, which are collectively tailored to address and improve a broad range of skin and body treatment needs including skin tightening, resurfacing, and rejuvenation. Solta Medical's commitment to innovation and a science-driven pursuit of excellence is boundless, and we are always exploring intellectual, scientific, and business possibilities. Follow us for brand and product updates and visit www.solta.com to learn more. See our Community Guidelines: www.bauschhealth.com/social-media/

SPECTRONRx provides therapeutic and diagnostic Isotopes for clinical and research use. They specialize in providing you flexible and efficient Contract Manufacturing and Contract Research services.COVID-19: EUA (O5/2020) Hymon SARS-CoV-2 Test Kit.

Starget Pharma is a clinical stage company developing a pipeline of radioligand therapy programs generated using its proprietary Backbone Dynamics peptide platform that leverages backbone cyclic innovations and in-silico AI to rapidly design highly specific Smart Targeted Radioligands (STRs) that deliver focused radiation for the imaging and treatment of hard-to-treat cancers.

Stratus® Medical's mission is to improve clinical outcomes for chronic pain patients by advancing RF technology for the treatment of pain. The Nimbus® RF Multitined Expandable Electrode, in combination with an RF Generator and Probe, are intended for use in radiofrequency (RF) heat lesion procedures for the treatment of pain. Nimbus creates a large volume and optimally shaped lesion. Nimbus provides faster procedure times, lower cost and reproducible and durable pain relief. The Nimbus RF procedure takes about 20 minutes and is completed in a procedure suite in the office, ASC or hospital outpatient department. Patients can be treated while awake with numbing medication or sedated, depending on physician and facility preference. Nimbus has 37 issued patents, several patents pending, is FDA cleared (class II) and is CE marked (class IIb). Nimbus has been utilized in over 250,000 patient treatments in the United States, Australia, Brazil, Canada, United Kingdom, and other countries. Stratus Medical also markets complimentary technology including Vesta®, Nimbus Probe and Nimbus Disposable Probe and has several exciting development projects underway. Copyright © Stratus Medical 2024 Nimbus®, Stratus® Medical & Advancing RF Technology for the Treatment Pain® are registered trademarks of Stratus Medical, LLC. *The Nimbus RF Multitined Expanandable Electrode is one treatment option for pain. Consult your physician for medical questions about your specific pain condition & treatment options. Nimbus RF results will vary. See IFU for full list of warnings and precautions.

Symple Surgical Inc., (SSI) is a developer of novel ablation technologies using controlled Microwave Energy. Symple Surgical innovation is for the treatment of resistant hypertension via renal sympathetic denervation. The DirectAblate Catheter delivers microwave energy to the depth-specific location of the sympathetic nerves while minimizing thermal exposure to non-targeted areas. Offices located in Northern California and Flagstaff, AZ.

TransCode's lofty goal is delivering a cancer-free future for all cancer patients. Our core belief is that cancer can be overcome through the intelligent design and efficient delivery of targeted therapeutics. Our lead therapeutic candidate, TTX-MC138, targets microRNA-10b, or miRNA-10b, considered the master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and several others. Our other preclinical programs include two solid tumor programs, TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1, or PD-L1, and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. TransCode also has three cancer agnostic programs, TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I, or RIG-I, targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. Until now, targeting biomarkers that are the primary drivers of cancer onset, progression and recurrence have been locked behind the challenge of delivery – cytosolic delivery to engage these known targets. TransCode believes it has overcome this barrier, opening the door to a broad array of cancer therapies -- a disease with the highest unmet need that affects everyone. It is through the design and optimization of this technology that TransCode has devised an elegant solution -- TTX -- a proprietary delivery platform for the transport of targeted therapeutics to cancer cells. With their world class team and know how, TransCode has a rapidly expanding platform of drug candidates designed to target a variety of tumor indications with the goal of long-term treatment survival.

Triad Isotopes is a manufacturer and supplier of radiopharmaceutical products.

Triad Isotopes is a manufacturer and supplier of radiopharmaceutical products.

TwoStep Therapeutics is developing novel tumor-targeting therapeutics for solid tumors.

Vascular Insights manufactures and commercializes medical devices for the treatment of peripheral vascular disease.

Xcision Medical Systems, LLC is a medical technology company that has developed the GammaPod, an advanced stereotactic radiotherapy system with the potential to significantly improve the convenience and quality of life for patients with early-stage breast cancer. The company's technology is designed to extend the benefits of radiation oncology to more patients and enable precision noninvasive treatments that allow patients to return to living fuller lives more quickly with less discomfort after receiving a cancer diagnosis. The system has been developed based on a patent licensed from the University of Maryland School of Medicine.